Evidence map›Paper›PMID 35262094›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses.

Michael S Seaman, Mark J Siedner, Julie Boucau, Christy L Lavine, Fadi Ghantous, May Y Liew, Josh Mathews, Arshdeep Singh, Caitlin Marino, James Regan and 19 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 23 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 6 institutions in 1 country.

Michael S SeamanBeth Israel Deaconess Medical Center, Boston, MA.
Mark J SiednerMassachusetts General Hospital, Boston, MA, USA.
Julie BoucauRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Christy L LavineBeth Israel Deaconess Medical Center, Boston, MA.
Fadi GhantousBeth Israel Deaconess Medical Center, Boston, MA.
May Y LiewMassachusetts General Hospital, Boston, MA, USA.
Josh MathewsMassachusetts General Hospital, Boston, MA, USA.
Arshdeep SinghMassachusetts General Hospital, Boston, MA, USA.
Caitlin MarinoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
James ReganBrigham and Women's Hospital Boston, MA, USA.
Rockib UddinMassachusetts General Hospital, Boston, MA, USA.
Manish C ChoudharyBrigham and Women's Hospital Boston, MA, USA.
James P FlynnBrigham and Women's Hospital Boston, MA, USA.
Geoffrey ChenMassachusetts General Hospital, Boston, MA, USA.
Ashley M StuckwischMassachusetts General Hospital, Boston, MA, USA.
Taryn LipinerMassachusetts General Hospital, Boston, MA, USA.
Autumn KittilsonBrigham and Women's Hospital Boston, MA, USA.
Meghan MelbergBrigham and Women's Hospital Boston, MA, USA.
Rebecca F GilbertMassachusetts General Hospital, Boston, MA, USA.
Zahra ReynoldsMassachusetts General Hospital, Boston, MA, USA.
Surabhi L IyerMassachusetts General Hospital, Boston, MA, USA.
Grace C ChamberlinMassachusetts General Hospital, Boston, MA, USA.
Tammy D VyasMassachusetts General Hospital, Boston, MA, USA.
Jatin M VyasMassachusetts General Hospital, Boston, MA, USA.
Marcia B GoldbergMassachusetts General Hospital, Boston, MA, USA.
Jeremy LubanUMass Med School, Worcester, MA, USA.
Jonathan Z LiBrigham and Women's Hospital Boston, MA, USA.
Amy K BarczakMassachusetts General Hospital, Boston, MA, USA.
Jacob E LemieuxHarvard Medical School, Boston, MA.
Massachusetts General Hospital · USBrigham and Women's Hospital · USHarvard University · USBeth Israel Deaconess Medical Center · USBroad Institute · USRagon Institute of MGH, MIT and Harvard · US

Funding

The HUSH complex in HIV-1 latencyR37AI147868 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI JEREMY LUBAN · 2019 to 2026
$6.4M
NIAID NIH HHS R37 AI147868
6 · The paper itself

Abstract

There is increasing evidence that the risk of SARS-CoV-2 infection among vaccinated individuals is variant-specific, suggesting that protective immunity against SARS-CoV-2 may differ by variant. We enrolled vaccinated (n = 39) and unvaccinated (n = 11) individuals with acute, symptomatic SARS-CoV-2 Delta or Omicron infection and performed SARS-CoV-2 viral load quantification, whole-genome sequencing, and variant-specific antibody characterization at the time of acute illness and convalescence. Viral load at the time of infection was inversely correlated with antibody binding and neutralizing antibody responses. Increases in antibody titers and neutralizing activity occurred at convalescence in a variant-specific manner. Across all variants tested, convalescent neutralization titers in unvaccinated individuals were markedly lower than in vaccinated individuals. For individuals infected with the Delta variant, neutralizing antibody responses were weakest against BA.2, whereas infection with Omicron BA.1 variant generated a broader response against all tested variants, including BA.2.

Identifiers

PMID35262094
PMCPMC8902886
OpenAlexW4214816219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.